# Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma

> **NCT03568929** · — · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 257 (actual)

## Conditions studied

- Follicular Non-Hodgkin's Lymphoma Refractory

## Interventions

- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT03568929
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-25
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568929, "Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03568929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*